Nevertheless, a multiple sclerosis patient treated with natalizumab has been reported to recover well from SARS-CoV-2 infection [26], which might be relevant to our finding that α4 integrin blockade abolished binding of S1 protein to monocytes. Here, PSMD1 is linked to multiple sclerosis.